利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

39 条记录 (耗时 0.015 秒)

    Human coagulation factor VII polypeptides
    1.
    发明申请
    Human coagulation factor VII polypeptides 失效
    人凝血因子VII多肽

    公开(公告)号：US20040192602A1

    公开(公告)日：2004-09-30

    申请号：US10669537

    申请日：2003-09-24

    发明人： Egon Persson ,  Ole Hvilsted Olsen

    IPC分类号： A61K038/37

    CPC分类号： C07K14/745 ,  A61K38/00

    摘要： The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.

    摘要翻译： 本发明涉及具有凝血活性的新型人凝血因子VIIa变体以及编码这样的变体，载体和宿主细胞的多核苷酸构建体，其包含并表达多核苷酸，药物组合物，用途和治疗方法。

    Use of activated coagulation factor Vll for treating thrombolytic therapy-induced major bleedings
    2.
    发明申请
    Use of activated coagulation factor Vll for treating thrombolytic therapy-induced major bleedings 审中-公开
    活化凝血因子Vll用于治疗溶栓治疗引起的主要出血

    公开(公告)号：US20040087502A1

    公开(公告)日：2004-05-06

    申请号：US10451615

    申请日：2003-12-18

    发明人： Cord Skamira ,  Jean Marie Stassen ,  Gerhard Heusel ,  Wolfgang Wienen

    IPC分类号： A61K038/37

    CPC分类号： A61K38/4846

    摘要： Major bleedings induced by thrombolytic/fibrinolytic therapy, including intracranial haemorrhages, are treated by administering to a subject suffering from such bleedings an effective amount of activated coagulation factor VII (VIIa) or a functional derivative thereof.

    摘要翻译： 通过对患有这种出血的受试者施用有效量的活化凝血因子VII（VIIa）或其功能衍生物来治疗由溶栓/纤维蛋白溶解治疗引起的主要出血，包括颅内出血。

    Method for inhibiting the formation of seromas using factor XIII
    4.
    发明申请
    Method for inhibiting the formation of seromas using factor XIII 失效
    使用因子XIII抑制血清肿形成的方法

    公开(公告)号：US20030087825A1

    公开(公告)日：2003-05-08

    申请号：US10268180

    申请日：2002-10-09

    发明人： Paul D. Bishop ,  Angelika Grossmann

    IPC分类号： A61K038/37

    CPC分类号： A61K38/45 ,  A61K38/4833 ,  A61K2300/00

    摘要： Use of factor XIII for inhibiting the formation of seromas by administering factor XIII. The factor XIII can be administered locally at the site of a wound or surgery or administered systemically. If the factor XIII is administered locally, it can be activated or non-activated and may be administered in conjunction with activated thrombin.

    摘要翻译： 使用因子XIII通过施用因子XIII抑制血清型的形成。 因子XIII可以在伤口或手术部位局部施用或全身给药。 如果因子XIII局部施用，则其可以被活化或未激活，并且可以与活化凝血酶联合施用。

    Method for treating coumarin-induced hemorrhage
    6.
    发明申请
    Method for treating coumarin-induced hemorrhage 失效
    香豆素引起的出血治疗方法

    公开(公告)号：US20040242480A1

    公开(公告)日：2004-12-02

    申请号：US10489082

    申请日：2004-03-05

    发明人： Paul D Bishop

    IPC分类号： A61K038/37

    CPC分类号： A61K38/45 ,  A61K38/14 ,  A61K2300/00

    摘要： Use of factor XIII for treating coumarin-induced hemorrhage or bleeding. The coumarin may be warfarin or dicoumarol. A patient having coumarin-induced bleeding is treated with factor XIII alone or in conjunction with vitamin K.

    摘要翻译： 使用因子XIII治疗香豆素引起的出血或出血。 香豆素可以是华法林或二西他赛。 使用单因素XIII或维生素K联合治疗香豆素引起的出血患者。

    Hemostatic composition
    8.
    发明申请
    Hemostatic composition 有权
    止血组成

    公开(公告)号：US20030224056A1

    公开(公告)日：2003-12-04

    申请号：US10157921

    申请日：2002-05-31

    发明人： Sanjay Kotha ,  Tirumalai S. Sudarshan

    IPC分类号： A61K038/37 ,  A61K009/14

    CPC分类号： A61L24/02 ,  A61K9/501 ,  A61K9/5094 ,  A61K38/4833 ,  A61K38/4846 ,  A61L2400/04

    摘要： A hemostatic composition includes a carrier medium including a predetermined amount of a particulate material. The particulate material is comprised of core particles with a coating. The core particles have an average particle size of about 5 nm to 10 nullm, and the coating is one of gold, silica, silver, platinum, steel, cobalt, carbon, a polymer, or a combination thereof.

    摘要翻译： 止血组合物包括包含预定量的颗粒材料的载体介质。 颗粒材料由具有涂层的核心颗粒组成。 核心颗粒具有约5nm至10μm的平均粒度，并且该涂层是金，二氧化硅，银，铂，钢，钴，碳，聚合物或其组合中的一种。

    Onset of force development as a marker of thrombin generation
    9.
    发明申请
    Onset of force development as a marker of thrombin generation 失效
    力量发展作为凝血酶生成的标志物

    公开(公告)号：US20030199428A1

    公开(公告)日：2003-10-23

    申请号：US10405472

    申请日：2003-04-03

    发明人： Marcus Carr JR.

    IPC分类号： A61K038/37 ,  C12Q001/56 ,  C12M001/34

    CPC分类号： C12Q1/56 ,  G01N33/4905 ,  G01N33/6893 ,  G01N33/80 ,  G01N33/86 ,  G01N2800/042 ,  G01N2800/226 ,  G01N2800/32 ,  G01N2800/324

    摘要： Platelet contractile force (PCF) is used as a surrogate marker of thrombin generation. PCF generation occurs concomitant with the burst of prothrombin fragment F 1null2 release. The time between assay start and PCF onset is identified as the thrombin generation time (TGT), and is used in assessing risk of bleeding, in diagnosing various disorders, and in monitoring the effects of pharmaceutical and other treatments. TGT is prolonged in clotting factor deficiencies and in the presence of direct and indirect thrombin inhibitors. TGT shortens to normal with clotting factor replacement and shortens with administration of rVIIa. TGT is short in thrombophilic states such as coronary artery disease, diabetes and thromboangiitis obliterans and prolongs toward normal with oral and intravenous anticoagulants.

    摘要翻译： 血小板收缩力（PCF）被用作凝血酶生成的替代标记物。 PCF产生伴随着凝血酶原片段F 1 + 2释放的爆发。 测定开始和PCF起始之间的时间被确定为凝血酶生成时间（TGT），并用于评估出血风险，诊断各种疾病以及监测药物和其他治疗的效果。 TGT在凝血因子缺乏症和直接和间接凝血酶抑制剂存在下延长。 TGT缩短至正常，凝血因子置换，并通过施用rVIIa缩短。 TGT在冠状动脉疾病，糖尿病和闭塞性血栓闭塞症等血栓形成状态较短，口服和静脉内抗凝剂延长至正常。